Brief: Clinuvel Pharmaceuticals Says European Medicines Agency Grants Orphan Drug Designation For Afamelanotide In Xeroderma Pigmentosum
29/04/2024 02:31
April 29 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* EUROPEAN MEDICINES AGENCY GRANTS ORPHAN DRUG DESIGNATION
FOR
AFAMELANOTIDE IN XERODERMA PIGMENTOSUM
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist